Search

Genodermatoses are diseases with significant psychosocial impact despite being relatively rare conditions, with a reported incidence that varies between 1:6000 and 1:500,000 [1] and is continually increasing, most likely due to the development of more effective diagnostic methods. Severity of the clinical expression of the genetic defects responsible for the occurrence of genodermatoses varies widely, with some cases taking the form of serious diseases that cause significant alteration of patients' quality of life, as well as that of their families, and also reduce the patients' life expectancy. Given the fact that genodermatoses are chronic, incurable diseases that are frequently associated with incapacitating disabilities and even with malignant degeneration potential, their management requires collaboration among members of a multidisciplinary team and a complex therapeutic regimen, which also demands considerable resources. Therefore, taking into account all these considerations, genodermatoses represent important public health issues. In the current paper we present the results of a prospective and retrospective study conducted between 2013 and 2023 on a number of 253 newly diagnosed patients with various clinical forms of genodermatoses, admitted to Dermatology departments in Bucharest. [ABSTRACT FROM AUTHOR]

Erythroderma is a severe skin condition characterized by a generalized erythematous rash covering more than 90% of the skin surface. It is associated with various underlying dermatological and systemic conditions. Diagnosis involves a comprehensive medical history, clinical examination and laboratory investigations. Erythroderma can be caused by the exacerbation of pre-existing skin conditions (e.g. psoriasis or atopic dermatitis) or by a drug hypersensitivity reaction, among other etiologies. In severe cases, it requires inpatient management to prevent complications such as dehydration, electrolyte imbalances and infections. Treatment includes addressing the underlying cause, supportive measures like fluid resuscitation and symptomatic relief using topical corticosteroids and antihistamines. Early diagnosis and targeted treatment are crucial for reducing the mortality and morbidity associated with this dermatological emergency. [ABSTRACT FROM AUTHOR]

Introduction: The diagnosis of erythroderma is frequently challenging due to subtle clinical and paraclinical signs necessary to differentiate between a variety of underlying dermatoses, infections or systemic diseases. The management is also difficult, with severe systemic complications that impose an early medical intervention. Objective: We aimed to analyze the epidemiological, clinical, and therapeutic profile of patients diagnosed with erythroderma in a tertiary dermatology referral center from Romania. Materials and methods: We conducted a retrospective descriptive study of patients diagnosed with erythroderma in the Dermatology and Allergology Clinic, „Elias" Emergency University Hospital, Bucharest, Romania from January 2012 to August 2018. An in-depth analysis of the clinical, paraclinical, as well as therapeutic management was performed. Results: The most frequent cause of erythroderma was represented by the exacerbation of psoriasis, followed by other chronic inflammatory dermatoses, as well as by hypersensitivity reactions to drugs. Less frequently, erythroderma was a paraneoplastic manifestation or a clinical presentation of rare genetic or autoimmune pathologies. The therapeutic management led to favorable results, with the remission or the amelioration of the disease. Few patients needed supportive care. Conclusions: Although the prognosis of the majority of patients was favorable, it is important to take into consideration the possibility of an associated cancer diagnosis. The dermatologist plays an essential role within the multidisciplinary team involved in the diagnosis and management of erythroderma. [ABSTRACT FROM AUTHOR]

Atopic dermatitis is a chronic inflammatory disease that affects both children and adults, with complex and multiple consequences on the individual and on society. Its main mechanism of production is the type 2 inflammation, which involves T helper 2 cells and innate lymphoid cells, and is exerted through several cytokines with various effects, the most important being IL-4 and IL-13. The knowledge of these events, acquired in recent years, has led to the emergence of revolutionary therapies, which today manage the proper control of this disease, including its moderate and severe forms. Dupixent (Dupilumab) is the first such therapy - a human IgG4 monoclonal antibody that inhibits the signalling performed by the 2 cytokines mentioned above. The effects of this inhibition are multiple, including the fast, sustained and significant improvement of the signs, symptoms and quality of life of these patients, whether adults or teenagers with a minimum age of 12 years, under a favourable safety profile and without the shortcomings of a cortisone or immunosuppressive medication. [ABSTRACT FROM AUTHOR]